Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Helyezés a részvények között #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Részvényárfolyam
$0.0416118
Piaci kapitalizáció
$12.78M
Változás (1 nap)
1.72%
Változás (1 év)
-22.01%
Ország
AU
Kereskedés Noxopharm Limited (NOX)

Kategória

Healthcare
Noxopharm Limited (NOX) P/S aránya
P/S arány ekkor: March 2026 TTM: 11.26
Noxopharm Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 11.26. 2024 végén ez az arány 8.04 volt.
P/S arány története a(z) Noxopharm Limited esetén 2016 és 2026 között
P/S arány az év végén
Év P/S arány Változtassa meg
2026 (TTM) 11.26 101.04%
2025 5.60 -30.33%
2024 8.04 284.34%
2023 2.09 -80.01%
2022 10.46 -65.53%
2021 30.35 1,000.90%
2020 2.76 -81.58%
2019 14.96 -78.61%
2018 69.96 -68.70%
2017 223.50 0.00%
2016 0.00 0.00%
P/S arány hasonló vállalatoknál vagy versenytársaknál
Vállalat P/S arány P/S arány különbség Ország
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -68.45%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -12.04%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -52.01%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -45.48%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -72.96%
AU